Search research articles
Contact Us
Filters
Showing results (21-30 of 105) with videos related to
Page
of 11
Sort By:
Nature Reviews. Clinical Oncology
|
June 17, 2026
Antibody-drug conjugates in gynaecological cancers: opportunities and challenges
Kathleen N Moore, Oladapo O Yeku, Brooke E Howitt, et al.
Gynecologic Oncology
|
October 5, 2020
Clinical assays for assessment of homologous recombination DNA repair deficiency
Elizabeth H Stover, Katherine Fuh, Panagiotis A Konstantinopoulos, et al.
Gynecologic Oncology
|
June 6, 2021
Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review
Angeles Alvarez Secord, David M O'Malley, Anil K Sood, et al.
Gynecologic Oncology
|
August 20, 2013
Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patients
Joyce F Liu, David Kindelberger, Courtney Doyle, et al.
Expert Opinion on Investigational Drugs
|
February 23, 2016
Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer
S Percy Ivy, Joyce F Liu, Jung-Min Lee, et al.
Gynecologic Oncology
|
June 21, 2011
Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas
Alison M Karst, Keren Levanon, Sekhar Duraisamy, et al.
Gynecologic Oncology
|
July 18, 2025
The RAS-MEK-ERK pathway in low-grade serous ovarian cancer
Elizabeth H Stover, Elizabeth K Lee, Geoffrey I Shapiro, et al.
Gynecologic Oncology
|
November 16, 2020
Lived experiences of women reporting fatigue during PARP inhibitor maintenance treatment for advanced ovarian cancer: A qualitative study
Hanneke Poort, Anny T H R Fenton, Embree Thompson, et al.
Oncoimmunology
|
May 4, 2016
Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model
De-Kuan Chang, Eric Peterson, Jiusong Sun, et al.
JCO Precision Oncology
|
June 5, 2020
Genomic Determinants of De Novo Resistance to Immune Checkpoint Blockade in Mismatch Repair-Deficient Endometrial Cancer
Doga C Gulhan, Elizabeth Garcia, Elizabeth K Lee, et al.
Page
of 11
Search research articles
Search
Showing results (21-30 of 105) with videos related to
Sort By:
Page
of 11
Nature Reviews. Clinical Oncology
|
June 17, 2026
Antibody-drug conjugates in gynaecological cancers: opportunities and challenges
Kathleen N Moore, Oladapo O Yeku, Brooke E Howitt, et al.
Gynecologic Oncology
|
October 5, 2020
Clinical assays for assessment of homologous recombination DNA repair deficiency
Elizabeth H Stover, Katherine Fuh, Panagiotis A Konstantinopoulos, et al.
Gynecologic Oncology
|
June 6, 2021
Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review
Angeles Alvarez Secord, David M O'Malley, Anil K Sood, et al.
Gynecologic Oncology
|
August 20, 2013
Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patients
Joyce F Liu, David Kindelberger, Courtney Doyle, et al.
Expert Opinion on Investigational Drugs
|
February 23, 2016
Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer
S Percy Ivy, Joyce F Liu, Jung-Min Lee, et al.
Gynecologic Oncology
|
June 21, 2011
Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas
Alison M Karst, Keren Levanon, Sekhar Duraisamy, et al.
Gynecologic Oncology
|
July 18, 2025
The RAS-MEK-ERK pathway in low-grade serous ovarian cancer
Elizabeth H Stover, Elizabeth K Lee, Geoffrey I Shapiro, et al.
Gynecologic Oncology
|
November 16, 2020
Lived experiences of women reporting fatigue during PARP inhibitor maintenance treatment for advanced ovarian cancer: A qualitative study
Hanneke Poort, Anny T H R Fenton, Embree Thompson, et al.
Oncoimmunology
|
May 4, 2016
Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model
De-Kuan Chang, Eric Peterson, Jiusong Sun, et al.
JCO Precision Oncology
|
June 5, 2020
Genomic Determinants of De Novo Resistance to Immune Checkpoint Blockade in Mismatch Repair-Deficient Endometrial Cancer
Doga C Gulhan, Elizabeth Garcia, Elizabeth K Lee, et al.
Page
of 11